Why Is BioNTech Stock Gaining Monday?
BioNTech (BNTX) Phase 3 data reveals gotistobart almost doubles survival in advanced lung cancer over standard docetaxel.
Stocks · News reference
Arbutus Biopharma Announces Filing Of Three International Lawsuits Seeking To Enforce Patents Protecting LNP Technology Against Pfizer, BioNTech And Certain Of Their Affiliates
Arbutus and its exclusive licensee, Genevant, filed three international lawsuits seeking to enforce patents protecting their innovative lipid nanoparticle ("LNP") technology against Pfizer and BioNTech Received
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
BioNTech And OncoC4's Gotistobart Shows Hazard Ratio Of 0.56 Versus Docetaxel In PRESERVE-003 Phase 3 Trial For Previously Treated Squamous Non-Small Cell Lung Cancer
Why Pfizer Stock Was so Healthy in August
Pfizer stock surged nearly 14% in August following better-than-expected Q2 earnings (revenue $15B vs. $14.4B expected, EPS $0.77 vs. $0.68 expected) and raised full-year revenue guidance. The company also achieved regulatory victories with EMA validation for a Lyme disease treatment and FDA approval for an updated COVID vaccine. Despite investor impatience over the lack of new blockbuster products, the analyst views Pfizer as undervalued with a promising pipeline from recent acquisitions.
This Best Buy Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Tuesday
Analysts downgraded BioNTech, Gulfport Energy, Amgen and Best Buy; price targets fell for BioNTech and Gulfport.
Should Dividend Investors Buy Pfizer Stock for Its High Yield or Invest in Eli Lilly for Its Dividend Growth?
The article compares two dividend investment strategies: Eli Lilly offers modest 0.6% yield but exceptional 15.3% annual dividend growth rate and strong growth prospects in the GLP-1 market, while Pfizer provides a high 6.2% yield with sustainable dividends backed by $11 billion in free cash flow. The choice depends on investor priorities—Eli Lilly suits those seeking growth and future dividend increases, while Pfizer appeals to investors prioritizing immediate income.
Co-development Deals in Pharmaceuticals and Biotechnology 2016-2026 | Pharmaceutical Co-Development Deals Reshape R&D Strategies as Companies Share Risk, Costs and Commercial Opportunities
A comprehensive market research report analyzing co-development deals in pharmaceuticals and biotechnology from 2016-2026 has been released. The report covers deal structures, financial terms, the top 25 most active dealmakers, and provides access to actual SEC-filed contract documents. Co-development partnerships are highlighted as a strategic approach for companies to share R&D costs, risks, and commercial opportunities while accelerating product development timelines.